Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cipla Ltd

CIPLA.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Large Cap Analyst: BUY

Last Close

$14.90

▼ -1.11%

Market Cap $12.00B · Vol 799.24K

Key Metrics

P/E Ratio

34.10

FWD: N/A

Market Cap

$12.00B

Large Cap

Div Yield

0.91%

Annual dividend

EPS Growth

-1.00%

YoY

RSI (14)

35.21

Momentum

Beta

0.66

vs Market

52W High

$17.53

21.82% below

52W Low

$12.22

18.84% above

Volume

799.24K

Avg 1.14M

P/B

2.87

Price-to-book

ROE

12.66%

Return on equity

Free Float

65.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cipla Ltd (CIPLA.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CIPLA.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.64%

+0.81%

+0.57%

+5.64%

YTD

-5.91%

-11.19%

+2.04%

+56.13%

Financials & Valuation

TTM · Annual

Total Revenue	$3.01B
Net Income	$414.07M
Revenue Growth (YoY)	+2.33%
Gross Margin	57.56%
Operating Margin	17.19%
Net Profit Margin	13.71%
ROE	12.66%
ROA · ROIC	13.08% · 11.68%

P/E Ratio	34.10
Forward P/E (FY1)	N/A
PEG Ratio	-0.97
P/S	3.51
P/B	2.87
P/FCF	94.54
EPS Growth	-1.00%
Outstanding Shares	807.85M

Technical Indicators

50-Day SMA	$15.06
200-Day SMA	$14.65
RSI (14)	35.21
Beta	0.66
52-Week High	$17.53
52-Week Low	$12.22

Volume Today	799.24K
Avg Daily Volume (30D)	1.14M
Relative Volume	0.70x
Volatility (10D)	10.61
Volatility (30D)	15.53
Free Float	65.42%

Analyst Consensus

BUY

Current Price $14.90

Mean Target $15.92

52W Low$12.22 52W High$17.53

Current

Target

$12.22 $17.53

Current Analyst target

+6.82% upside potential · 38 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S832Y4

ISININE059A01026

CountryIndia

Sub-IndustryGeneric Pharmaceuticals

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

SUNPHARMA.NS Sun Pharmaceutical Industries Ltd +0.63% 4578.T Otsuka Holdings Co Ltd -0.98% ZYDUSLIFE.NS Zydus Lifesciences Ltd +1.88% RICHTER.BU Richter Gedeon Vegyeszeti Gyar Nyrt +0.23% 4528.T Ono Pharmaceutical Co Ltd +0.61%

Company Profile

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.